SSTR5 and neoplasm: Thus, it is reasonable to speculate that a combined SSTR5-based tumor therapeutic approach including both somatostatin analog and other inhibiting technology of PDX-1 [for example, RNA interference control of PDX-1 (Liu et al., 2008)] would help improve the traditional treatment with somatostatin analogs.